Navigation Links
Stopping Blood Thinners Raises Stroke Risk for Patients With Irregular Heartbeat
Date:4/25/2012

By Steven Reinberg
HealthDay Reporter

WEDNESDAY, April 25 (HealthDay News) -- When patients with atrial fibrillation stop taking anti-clotting drugs, their stroke risk goes up quickly, new research finds.

That risk increases about the same whether they are taking warfarin or a newer, more expensive drug, Xarelto (rivaroxaban).

Atrial fibrillation is an abnormal heart rhythm in which the upper chambers of the heart quiver or flutter instead of contracting correctly, raising the risk of stroke fivefold. Patients are often put on anti-clotting drugs to ward off stroke.

But some people need to temporarily stop taking anti-clotting drugs before surgery or other medical procedures to prevent excess bleeding, while other patients permanently stop taking anti-clotting drugs because of side effects, researchers said.

Researchers analyzed data from a previous trial including more than 14,000 patients with atrial fibrillation. In that trial, rivaroxaban was found to be as effective as warfarin in preventing stroke and blood clots. Both drugs carried about an equal risk of causing excessive bleeding.

In the new study, researchers concentrated on patients who had stopped taking the drugs, either temporarily or permanently. Regardless of which drug was stopped, the rate of strokes and blood clots went up about the same.

Decisions to halt either warfarin or rivaroxaban should be made carefully, since going off the drugs means the heightened stroke risk associated with atrial fibrillation returns, said lead researcher Dr. Manesh Patel, an assistant professor of medicine at Duke University School of Medicine.

"All anticoagulation decisions in patients with atrial fibrillation require risk benefit analysis, and for patients and physicians periods without anticoagulation coverage should be minimized," Patel said.

The study was to be presented Wednesday at the American Heart Association Emerging Science Series.

Atrial fibrillation affects more than 2.3 million men and women in the United States and accounts for more than 15 percent of all strokes, said Dr. Gregg Fonarow, a professor of cardiology at the University of California, Los Angeles. Anticoagulation therapy reduces the risk of stroke by 60 to 80 percent in patients with atrial fibrillation, Fonarow said.

Yet there are key differences between the older and the new drug, including price and how much monitoring is needed, experts said.

Patients taking warfarin need to have the levels of the drug monitored and adjusted regularly to insure it is being effective and not increasing the risk of serious bleeding, while patients taking rivaroxaban don't require as careful monitoring.

"While the newer oral anticoagulants rivaroxaban and dabigatran (Pradaxa) cost approximately $250 a month compared with warfarin, which costs only a few dollars a month, these new agents have the advantage of not requiring monthly blood draws and providing more reliable anticoagulation," Fonarow said.

Because this research has not yet been published, it has not been subjected to the rigorous scrutiny given to research published in peer-reviewed medical journals and should be viewed as preliminary.

The study was partly funded by Johnson & Johnson and Bayer HealthCare AG, which makes rivaroxaban.

More information

The American Heart Association has more on atrial fibrillation.

SOURCES: Manesh Patel, M.D., assistant professor, medicine, Duke University School of Medicine, Durham, N.C.; Gregg Fonarow, M.D., professor, cardiology, University of California, Los Angeles; April 25, 2012, presentation, American Heart Association's Emerging Science Series


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Coaching Boys into Men an effective tool for stopping teen dating violence
2. Stopping hormones might help breast cancer to regress
3. Cell signaling key to stopping growth and migration of brain cancer cells
4. Selectively stopping glutathione sensitizes brain tumors to chemotherapy
5. Hand-Washing Key to Stopping Spread of Disease
6. Some States Make Stopping Smoking Easier Than Others
7. Stopping dangerous cell regrowth reduces risk of further heart attacks
8. Stopping Daily Aspirin Boosts Heart Attack Risk: Study
9. ACP commends Congress for preserving patient access by stopping scheduled Medicare SGR cuts
10. Internists issue heartfelt plea for Congress to help patients by stopping Medicare SGR cuts
11. Researchers find new target for stopping tumors developing their own blood supply
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica ... Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs ... Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, ...
(Date:6/25/2016)... ... , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors ... Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green ... hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Research and Markets has announced the addition ... 2022" report to their offering. ... with kidney failure, it replaces the function of kidneys by ... and thus the treatment helps to keep the patient body,s ... Increasing number of ESRD patients & substantial healthcare ...
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
Breaking Medicine Technology: